Efficacy and long‐term safety
The median PFS was 6.8 months (95% CI, 4.0–8.6 months) and median OS was 21.6 months (95% CI, 17.0 months to not reached) (Figures Progression‐free survival after enrollment in the study. The median progression‐free survival time was 6.8 months and median follow‐up time was 6.2 months.Overall survival after enrollment in the study. The median overall survival time was 21.6 months and median follow‐up time was 15.3 months.